Cargando…
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
Angiogenesis is a hallmark of cancer development. This study sought to determine the recommended dose of aflibercept, a recombinant fusion protein targeting VEGF-A, VEGF-B and placental growth factor (PlGF), combined with docetaxel in Japanese patients with advanced solid malignancies. This phase I...
Autores principales: | Sunakawa, Yu, Takahashi, Keishiro, Kawaguchi, Osamu, Yamamoto, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395466/ https://www.ncbi.nlm.nih.gov/pubmed/35771301 http://dx.doi.org/10.1007/s10637-022-01267-x |
Ejemplares similares
-
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
por: Doi, Toshihiko, et al.
Publicado: (2020) -
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012) -
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000) -
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012) -
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998)